News & Events
Powering the AI Revolution for Drug Discovery with High-Quality Empirical Data
In this webinar, 1859 will discuss its approach to rapidly generating high-quality, empirical, small molecule datasets, and its comparison to other approaches, like public data curation and traditional screening technology. In addition, the panel will walk through case studies that show how this data accelerates drug discovery at Hit ID through Lead OP.
Using Machine Learning to Find Potential Lead Molecules
Join us at this dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Hear presentations on targeting transcription factors, plus greatly expanded coverage of protein degraders, molecular glues, and artificial intelligence for early drug discovery.
Catalyzing Drug Discovery with AI and Scaled Chemical Libraries with a Cayer
In this podcast, Axial VC founder Joshua Elkington talks with Devon Cayer, 1859’s cofounder and company leader, about Devon’s inspirations, motivations, and innovations that set his trajectory as an entrepreneur and Founder of 1859. The underlying technology of 1859 relies on Devon’s and his co-founders’ expertise in combinatorial library preparation, pico-scale activity-based screening to create SAR models for each compound, and machine learning of iterative screens of titrated compounds to predict the best leads.